Cargando…

Characterizing Safety and Clinical Outcomes Associated with High-Dose Micafungin Utilization in Patients with Proven Invasive Candidiasis

Micafungin is the empiric antifungal agent of choice for the treatment of invasive candidiasis (IC). Pathophysiologic changes that occur in obese and/or critically ill patients can alter micafungin serum concentrations and the probability of target attainment. Although high doses of micafungin have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grant, Victoria C., Nguyen, Kenneth, Rodriguez, Sasha, Zhou, Anna Y., Abdul-Mutakabbir, Jacinda C., Tan, Karen K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878997/ https://www.ncbi.nlm.nih.gov/pubmed/35202218 http://dx.doi.org/10.3390/tropicalmed7020023

Ejemplares similares

Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
por: Wiederhold, Nathan P, et al.
Publicado: (2009)

Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidaemia
por: Kuse, ER, et al.
Publicado: (2008)

Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study
por: Viscoli, Claudio, et al.
Publicado: (2014)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)

Plasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies
por: De Rose, Domenico Umberto, et al.
Publicado: (2023)

Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin
por: Kebriaei, Razieh, et al.
Publicado: (2023)

Cardiac Safety of High-dose Micafungin
por: Stover, Kayla R., et al.
Publicado: (2017)

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study
por: van der Geest, Patrick J., et al.
Publicado: (2016)

A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis
por: Benjamin, Daniel K., et al.
Publicado: (2018)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature
por: Wilke, MH
Publicado: (2011)

A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis
por: Kohno, S., et al.
Publicado: (2012)

Impact of early catheter removal during treatment of invasive candidiasis: analysis from two phase 3 micafungin trials
por: Nucci, M, et al.
Publicado: (2009)

Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis: A non-comparative, multicenter, phase IV, open-label study
por: Ji, Yu, et al.
Publicado: (2017)

1412. Racial Differences in Candidemic Patients at a Southern California Teaching Hospital
por: Grant, Victoria C, et al.
Publicado: (2022)

Racial disparities among candidemic patients at a Southern California teaching hospital
por: Grant, Victoria C., et al.
Publicado: (2023)

Pooled analysis of safety for micafungin
por: Cornely, OA, et al.
Publicado: (2008)

Exposure–Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials
por: Kovanda, Laura L., et al.
Publicado: (2018)

1858. Examining the Racial Differences in Polymicrobial Bacteremia Infections in an Area of Varying Social Vulnerability
por: Tan, Karen K, et al.
Publicado: (2023)

Evaluation of Candida peritonitis with underlying peritoneal fibrosis and efficacy of micafungin in murine models of intra-abdominal candidiasis
por: Ashizawa, Nobuyuki, et al.
Publicado: (2019)

Are we near to the end of the standard dose of micafungin?
por: Agrifoglio, Alexander, et al.
Publicado: (2018)

Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study
por: Leroy, Olivier, et al.
Publicado: (2016)

Micafungin for the treatment of pediatric invasive fungal infections
por: Arrieta, A, et al.
Publicado: (2009)

Exploring the intersection of racism, antimicrobial resistance, and vaccine equity
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2022)

Demographic and outcome differences in ICU patients with proven invasive candidiasis, possible invasive candidiasis and probable candida colonization: analysis of the EPIC II study population
por: Kett, D, et al.
Publicado: (2011)

Treatment with Micafungin in a Preterm Neonate with an Invasive Candida parapsilosis Infection after a Severe Terlipressin-Induced Skin Necrosis
por: De Rose, Domenico Umberto, et al.
Publicado: (2021)

Identifying the potential impact of a multidisciplinary outpatient antimicrobial therapy program in an area of high social vulnerability
por: Tan, Karen K., et al.
Publicado: (2023)

Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
por: Dupont, Bertrand F, et al.
Publicado: (2009)

Micafungin induced apoptosis in Candida parapsilosis independent of its susceptibility to micafungin
por: Shirazi, Fazal, et al.
Publicado: (2015)

Slowed progression: The utility of Test to Treat initiatives in improving the neglected inequities of COVID-19 among racially/ethnically minoritized groups
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2023)

Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication
por: Nakajima, Shogo, et al.
Publicado: (2023)

Successful treatment of pulmonary candidiasis and aspergillosis in patient with refractory Hodgkin lymphoma using micafungin – case study and brief literature review
por: Barańska, Marta, et al.
Publicado: (2017)

Safety, Efficacy, and Exposure–Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis
por: Martin, Judith M., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Effectiveness and Safety of Micafungin in Managing Invasive Fungal Infections among Patients in Greece with Hematologic Disorders: The ASPIRE Study
por: Kotsopoulou, Maria, et al.
Publicado: (2019)

Safety and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children
por: Roilides, Emmanuel, et al.
Publicado: (2017)

Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies?
por: Honore, Patrick M., et al.
Publicado: (2018)

Invasive Candidiasis in Severe Acute Pancreatitis: Experience from a Tertiary Care Teaching Hospital
por: Baronia, Arvind Kumar, et al.
Publicado: (2017)

Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
por: Kofla, G, et al.
Publicado: (2011)

Review of the pharmacology and clinical studies of micafungin
por: Bormann, Alison M, et al.
Publicado: (2009)

Pharmacokinetics of Micafungin in Critically Ill Patients
por: Gastine, Silke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j8eaetjtisl9hjnbuts6rri0lq